Vaxart logo
Vaxart VXRT

Quarterly report 2025-Q3
added 11-13-2025

report update icon

Vaxart Income Statement 2011-2025 | VXRT

Annual Income Statement Vaxart

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

159 M 99.6 M 617 M 1.29 B 15.7 M 12.4 M 20.5 M 52.9 M 81.3 M 103 M 105 M - 69.9 M

Shares

145 M 128 M 121 M 88.3 M 21.6 M 6.32 M 3.51 M 3.51 M 3.21 M 2.85 M 2.57 M - 641 K

Historical Prices

1.1 0.78 5.08 7.15 2.87 1.72 5.59 6.49 16.9 27.7 72.8 43.9 111

Net Income

-82.5 M -108 M -70.5 M -32.2 K -18.6 M -18 M -29.4 M -25.4 M -19.1 M -11 M -8.7 M - -4.53 M

Revenue

7.38 M 107 K 892 K 4.05 K 9.86 M 4.16 M 8.9 M 9.3 M 24.6 M 68.7 M 33.6 M - 14.8 M

Gross Profit

- - - 4.05 K - - - 9.3 M 21 M 17.6 M 13.2 M - 13.4 M

Operating Income

-83.3 M -115 M -72.8 M -30.2 M -15.8 M -21.8 M -10 M -25.2 M -19.5 M -11.5 M -22.1 M -22.9 M -9.76 M

Interest Expense

- - - - 315 K 821 K 3.04 M - - - - - 37 K

EBITDA

-74.7 M -109 M -68.5 M -29.3 K -7.27 M -17 M -27.3 M -24.9 M -7.1 M -7.7 M -16.6 M - -9.52 M

Operating Expenses

90.7 M 115 M 73.6 M 34.2 K 20.7 M 24.3 M 36.3 M 34.3 M 29.2 M 27.7 M 32.8 M - 23.1 M

General and Administrative Expenses

22.6 M 29.4 M 21.9 M 15.2 K 6.19 M 7.04 M 5.7 M 5.6 M 6.6 M 6.9 M 13.6 M - 5.37 M

All numbers in USD currency

Quarterly Income Statement Vaxart

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

229 M 228 M 228 M 228 M 227 M 185 M 169 M 153 M 152 M 140 M 135 M 134 M 127 M 126 M 126 M 126 M 124 M 121 M 115 M 110 M 108 M 74.7 M 60.7 M 48.3 M 16.2 M 14.6 M 7.3 M 7.14 M 7.14 M 7.14 M 3.66 M 38.6 M 38.6 M 38.6 M 136 K 38.6 M 38.6 M 38.6 M 38.6 M 38.6 M 38.6 M 38.6 M 38.6 M 35.1 M 35 M 35.1 M 35 M 28.3 M 28.3 M 28.3 M 28.3 M 28.1 M 22.8 M 28.1 M 22.7 M 22.7 M 42.4 M 42.3 K 42.1 M

Net Income

-8.14 M -15 M -15.6 M - -14.1 M -16.5 M -24.4 M - -17.4 M -22.6 M -25.1 M - -29.3 M -29.4 M -25.1 M -20.8 M -17.6 M -16.1 M -16 M -13.9 M -8.08 M -8.98 M -1.3 M -6.41 M -5.26 M -5.64 M -1.34 M -4.9 M -6.55 M -8.87 M 2.31 M -1.08 M -2.17 M -3.4 M -5.3 M -9.1 M -10 M -9.1 M -10 M -6.5 M -6.6 M -6.5 M -6.6 M 6.5 M -6.9 M 6.5 M -6.9 M -100 K -3.9 M -100 K -3.9 M 4.6 M -7.2 M 4.83 M -2.04 M -7.06 M 78 K -4.6 M 1.98 M

Revenue

72.4 M 39.7 M 20.9 M - 4.93 M 6.4 M 2.18 M - 2.1 M 1.36 M 675 K - - - 85 K 74 K 200 K 112 K 506 K 356 K 265 K 523 K 2.9 M 3.92 M 454 K 85 K 5.41 M 1.77 M 281 K 608 K 1.5 M 760 K 915 K 2.7 M 100 K 3.8 M 100 K 3.8 M 100 K 1.7 M 1.7 M 1.7 M 1.7 M 13.9 M 700 K 13.9 M 700 K 18.5 M 12.2 M 18.5 M 12.3 M 10.4 M 1.4 M 10.4 M 7.09 M 2.09 M 1.09 M 3.74 M 9.17 M

Cost of Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 7.4 M 10.5 M 8.2 M 8.4 M 24.1 M 4.8 M 7.5 M 7.7 M 19 M 26.3 M 18.6 M 16.3 M 7.7 M 4.1 M 7.1 M 1.5 M - - - - - -

Operating Income

-7.81 M -14.6 M -14.9 M - -14.5 M -16.3 M -24.1 M - -17.8 M -23.1 M -25.6 M - -29.4 M -29.2 M -24.8 M - -17.3 M -15.8 M -15.5 M - -7.59 M -8.53 M -694 K - -4.71 M -5 M -448 K - -5.88 M -7.78 M -3.92 M -2.9 M -1.96 M -7.9 M -5 M -8.6 M -9.6 M -8.6 M -9.6 M -6.5 M -6.7 M -6.5 M -6.7 M 6.4 M -7 M 6.4 M -7 M -100 K -4.1 M -100 K -4.1 M -7.8 M -7.8 M -7.82 M -2.63 M -8.42 M -4.94 M -4.69 M 1.87 M

Interest Expense

-7 K -1 K -1 K - 22 K 5 K -1 K - - - - - - - - - - - - - - - - - 84 K 97 K 107 K - 129 K 136 K 437 K - 768 K 755 K 744 K - - - - - - - - - - - - - - - - - -2 K 109 K 33 K - -17 K 38 K 37 K

EBITDA

-6.91 M -13.7 M -12.7 M - -13.5 M -15.4 M -21.9 M - -16.8 M -22.2 M -23.5 M - -28.9 M -28.8 M -23.6 M - -17 M -13.8 M -14.5 M - -5.74 M -7.33 M -114 K - -1.86 M -2.9 M 652 K - -3.5 M -6.34 M -3.4 M -2.9 M -1.66 M -7.7 M -4.9 M -8.6 M -9.6 M -8.6 M -9.6 M -6.5 M -5.6 M -6.5 M -6.7 M 6.4 M -6.6 M 7.2 M -6.6 M -100 K -3.6 M 900 K -3.6 M -7.8 M -7.2 M -6.28 M -2.61 M -8.42 M -4.81 M -4.58 M 1.94 M

Operating Expenses

80.2 M 54.3 M 35.8 M - 19.4 M 22.7 M 26.3 M - 19.9 M 24.4 M 26.2 M - 29.4 M 29.2 M 24.9 M 24.3 M 17.5 M 15.9 M 16 M 13.7 M 7.85 M 9.05 M 3.6 M 9.54 M 5.17 M 5.08 M 5.86 M 5.95 M 6.16 M 8.38 M 5.42 M 3.45 M 2.87 M 4.98 M 4.56 M - - - - - - - - - - - - - - - - - 4.75 M 3.51 M 2.8 M - 6.02 M 8.43 M 7.3 M

General and Administrative Expenses

4.28 M 4.6 M 5.07 M - 4.34 M 5.18 M 7.24 M - 4.92 M 5.6 M 6.62 M - 6.96 M 9.32 M 6.66 M - 5.04 M 5.15 M 5.94 M - 4.19 M 3.9 M 1.99 M - 1.46 M 1.38 M 2.03 M - 1.67 M 1.77 M 2.01 M 3.1 M 624 K 5.4 M 2.3 M 2.1 M 2.2 M 2.1 M 2.2 M 2.1 M 2.2 M 2.1 M 2.2 M 2.6 M 2.4 M 2.6 M 2.4 M 3.1 M 2.4 M 3.1 M 2.4 M 7.1 M 3.2 M 7.08 M 2.22 M 1.85 M 1.29 M 1.43 M 1.34 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Vaxart (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Pharming Group N.V. Pharming Group N.V.
PHAR
$ 17.91 -1.0 % $ 7.59 B niderlandNiderland
InflaRx N.V. InflaRx N.V.
IFRX
$ 1.09 -4.82 % $ 152 M germanyGermany
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aptorum Group Limited Aptorum Group Limited
APM
$ 1.15 -1.71 % $ 6.27 M chinaChina
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.78 -0.31 % $ 793 M canadaCanada
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.03 -0.49 % $ 234 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 209.39 -1.61 % $ 5 B danmarkDanmark
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 0.6 -35.8 % $ 166 K usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.66 -1.49 % $ 424 M britainBritain
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.12 0.81 % $ 7.51 B australiaAustralia
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
BioVie BioVie
BIVI
$ 1.2 -5.51 % $ 1.77 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 0.22 24.46 % $ 479 M israelIsrael
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 94.72 -0.33 % $ 27.2 B germanyGermany
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 27.09 1.04 % $ 1.31 B usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 9.6 1.27 % $ 141 M usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Zai Lab Limited Zai Lab Limited
ZLAB
$ 18.4 -0.97 % $ 18.2 B chinaChina
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 12.33 -0.29 % $ 812 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 584.81 -1.07 % $ 44.3 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.44 -3.56 % $ 15.3 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
$ 92.79 0.37 % $ 96.9 B britainBritain
ChromaDex Corporation ChromaDex Corporation
CDXC
- -0.88 % $ 598 M usaUSA
Certara Certara
CERT
$ 8.9 -0.17 % $ 1.43 B usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA